EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modular Assembly of Systems for Antibody-Directed Enzyme Prodrug Therapy

Maura E Charette iD, Madelyn H Ratesic iD, Gianna N Falcone, Grace V Lewis, Isabella R Demyan, Sagar D Khare, Alexander Deiters iD

ACS Chemical Biology · 2026

DOI: 10.1021/acschembio.6c00539 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Biology, 2026. Verfasst von Maura E Charette und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania15260, United States. Hauptthemen laut MEDLINE: Prodrugs, Immunoconjugates, Antineoplastic Agents, Antibodies. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-directed enzyme prodrug therapy (ADEPT) utilizes a cancer-targeting antibody–enzyme conjugate to selectively activate a prodrug at the site of a tumor. We developed a modular plug-and-play approach for the generation of ADEPT antibody–enzyme conjugates that pairs a self-labeling SNAPtag-enzyme fusion with a benzylguanine-tagged antibody for rapid generation of a series of conjugates for testing. This approach enables the fusion of pharmacy-grade antibodies that are site-specifically modified with a recombinantly expressed enzyme using bioorthogonal self-labeling chemistry. The biorthogonality of the final assembly step of the ADEPT system even provides the ability for antibody–enzyme pairing in situ in the target cellular environment, improving ease of testing and potentially improving in vivo pharmokinetics. We have demonstrated conjugate formation and localization to antigen-positive cells, retained enzymatic activity upon conjugate cell surface binding, and ultimately selective killing of tumor cells. Additionally, this modular assembly allowed us to construct conditionally controlled ADEPT systems through site-specific incorporation of a light-cleavable protecting group, pairing a caged enzyme with a caged prodrug to create Boolean AND logic, potentially increasing the therapeutic window by providing conditional control over cytotoxic drug activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsImmunoconjugatesAntineoplastic AgentsAntibodiesHumansCell Line, TumorAnimals

Substanzen

ProdrugsImmunoconjugatesAntineoplastic AgentsAntibodies

Autor:innen und Institutionen

  • Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania15260, United States.
  • Institute for Synthetic Biology, University of Pittsburgh, Pittsburgh, Pennsylvania15260, United States.
  • Department of Chemistry, Rutgers University, Piscataway, New Jersey08854, United States.

ORCID-Profile: Maura E Charette, Madelyn H Ratesic, Alexander Deiters

Förderung

  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Zitieren

APA

Charette, M. E., Ratesic, M. H., Falcone, G. N., Lewis, G. V., Demyan, I. R., Khare, S. D., & Deiters, A. (2026). Modular Assembly of Systems for Antibody-Directed Enzyme Prodrug Therapy. ACS Chemical Biology. https://doi.org/10.1021/acschembio.6c00539

Vancouver

Charette ME, Ratesic MH, Falcone GN, Lewis GV, Demyan IR, Khare SD, et al. Modular Assembly of Systems for Antibody-Directed Enzyme Prodrug Therapy. ACS Chemical Biology. 2026. doi:10.1021/acschembio.6c00539

BibTeX
@article{Charette2026,
  author = {Charette, Maura E and Ratesic, Madelyn H and Falcone, Gianna N and Lewis, Grace V and Demyan, Isabella R and Khare, Sagar D and Deiters, Alexander},
  title = {Modular Assembly of Systems for Antibody-Directed Enzyme Prodrug Therapy},
  journal = {ACS Chemical Biology},
  year = {2026},
  doi = {10.1021/acschembio.6c00539}
}
Kostenlos starten →